The FAME 2 trial compared fractional flow reserve (FFR)-guided percutaneous coronary intervention plus medical therapy with medical therapy alone in patients with stable coronary artery disease. Long-term follow-up showed that the FFR-guided intervention group had fewer cardiovascular events. The main benefit was a reduction in emergency revascularization events. The study was published in Nature Medicine online on January 15, 2026 with DOI: 10.1038/s41591-025-04132-5. Fractional flow reserve is used to evaluate the significance of coronary artery narrowing. These results confirm the advantage of the combined strategy over drug treatment alone.